Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA
Retrieved on:
Thursday, January 6, 2022
COVID-19, Department of Oncology, University of Cambridge, Immune system, Cancer, Infection, U.S. Securities and Exchange Commission, Prognosis, Survival, NASDAQ, FDA, FCGR3A, New Drug Application, National Medical Products Administration, Coronavirus, Trastuzumab, CSCO, Breast, Private Securities Litigation Reform Act, Food and Drug Administration, Progression-free survival, HER2, Population, NDA, Safety, FC, Margetuximab, Food, Forward-looking statement, Patient, Hospital, FCGR2B, PFS, MD, Health, Degenerative disease, Macrogen, NMPA, SAN, GLOBE, Breast cancer, CD32B, Adult, HER2/neu, Risk, Department, Woman, NK, ADCC, Death, Pharmaceutical industry, Medical imaging, SOPHIA
The potential approval of margetuximab will also be an important addition to our growing womens oncology franchise and marks Zai Labs sixth NDA acceptance by the NMPA.
Key Points:
- The potential approval of margetuximab will also be an important addition to our growing womens oncology franchise and marks Zai Labs sixth NDA acceptance by the NMPA.
- Zai Labs bridging study confirmed the clinical benefit of margetuximab in Chinese patients.
- We are excited to see this potential new treatment option for patients living with metastatic breast cancer in China."
- Breast cancer is the most common cancer in Chinese women, with 416,371 newly diagnosed cases and 117,174 deaths in 20201.